Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

The Gate Keeper: Dr. David Haslam, Chair of NICE, UK

October 1, 2014

NICE's David Haslam discusses the UK drug watchdog's new challenge in meeting expectations around what quantitative calculations of value mean to patient access today.

Crowdfunding: The Open-Source Option Against Capital Crunch

October 1, 2014

Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.

"Sunshine" Goes Live — Despite Incomplete Information

October 1, 2014

The federal Open Payments program has gone live, but biopharma companies continue to be concerned about the lack of context. Jill Wechsler reports.

Investing in African Healthcare: Study, Share, Act — and Grow

September 18, 2014

Is sub-Saharan Africa a jewel box of untapped assets for a growth-obsessed big Pharma? Pharm Exec speaks with Steven Adjei, partner of an investment firm focused on opportunities in the region.

Pharm Exec Global Digest: Technology Special

September 4, 2014

A new transatlantic initiative for start-ups, the medical technology 'disconnect', and the latest developments in wearable healthcare technology are covered in the new issue of Pharm Exec Global Digest.

Executive Coaching: Transforming Big Pharma from Within

September 3, 2014

Rick Koonce outlines the critical coaching steps to help top managers realize their potential in an industry undergoing significant restructuring of both human and financial capital.

Pharma Battles Hospitals Over Discount Pricing Program

September 3, 2014

Continued growth in a program that provides low-cost drugs to safety-net hospitals has sparked "trench warfare" over which medicines and providers are eligible for the discounts, writes Jill Wechsler.

Ireland's Celtic Tiger: Back on the Hunt

September 1, 2014

Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.

Pharm Exec's 13th Annual Industry Audit

September 1, 2014

After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.

ADVERTISEMENT

Click here